ArticleScientific reports2022
Identification of vaccine and drug targets in Shigella dysenteriae sd197 using reverse vaccinology approach.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Computational systems immunology and multi-scale modeling for the design of a Multi-Epitope Vaccine (MEV) against emerging multidrug-resistant Klebsiella michiganensis.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Designing a Multi-Epitope Vaccine Candidate AgainstVeterinary sciences · 2026Article
- Immunoinformatics-based design of a next generation multi-epitope vaccine candidate against Shigella boydii using a hierarchical subtractive proteomics approach.Scientific reports · 2025Article
- Immunoinformatics investigation on pathogenic Escherichia coli proteome to develop an epitope-based peptide vaccine candidate.Molecular diversity · 2025Article
- Subtractive proteo-genomics and model-based druggability analyses prioritized nitrate reductase-A subunit-α as potential therapeutic target against MDR pneumonia; a homology-based approach.BMC microbiology · 2025Article
- Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice.NPJ vaccines · 2025Article
- Computational Strategies in Drug Discovery: Leveraging Subtractive Genomic Analysis for Target Identification.Current pharmaceutical biotechnology · 2025Review
- Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets againstFrontiers in immunology · 2025Article
- In Silico Subtractive Proteome Analysis to Design Multi-Epitope-Based Subunit Vaccine againstJournal of microbiology and biotechnology · 2024Article
- Outer membrane protein C is a protective and unique vaccine antigen against Shigella flexneri 3a.Scientific reports · 2024Article
- Beyond Antibiotics: What the Future Holds.Antibiotics (Basel, Switzerland) · 2024Review
- Evaluation of vaccine candidates against Rhodococcus equi in BALB/c mice infection model: cellular and humoral immune responses.BMC microbiology · 2024Article
- PBITProtein science : a publication of the Protein Society · 2024Article
- Integrating core subtractive proteomics and reverse vaccinology for multi-epitope vaccine design against Rickettsia prowazekii endemic typhus.Immunologic research · 2024Article
- Designing a multi-epitope vaccine againstFrontiers in genetics · 2024Article
- An integrated in-silico approach for drug target identification in human pathogen Shigella dysenteriae.PloS one · 2024Article
- Bioinformatics Approaches in the Development of Antifungal Therapeutics and Vaccines.Current genomics · 2024Review
- Article
- Deciphering the Immunogenicity of Monkeypox Proteins for Designing the Potential mRNA Vaccine.ACS omega · 2023Article
- Mining gene expression data for rational identification of novel drug targets and vaccine candidates against the cattle tick, Rhipicephalus microplus.Experimental & applied acarology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Shigellosis is characterized as diarrheal disease that causes a high mortality rate especially in children, elderly and immunocompromised patients. More recently, the World Health Organization advised safe vaccine designing against shigellosis due to the emergence of Shigella dysenteriae resistant strains. Therefore, the aim of this study is to identify novel drug targets as well as the design of the potential vaccine candidates and chimeric vaccine models against Shigella dysenteriae. A computational based Reverse Vaccinology along with subtractive genomics analysis is one of the robust approaches used for the prioritization of drug targets and vaccine candidates through direct screening of genome sequence assemblies. Herein, a successfully designed peptide-based novel highly antigenic chimeric vaccine candidate against Shigella dysenteriae sd197 strain is proposed. The study resulted in six epitopes from outer membrane WP_000188255.1 (Fe (3+) dicitrate transport protein FecA) that ultimately leads to the construction of twelve vaccine models. Moreover, V9 construct was found to be highly immunogenic, non-toxic, non-allergenic, highly antigenic, and most stable in terms of molecular docking and simulation studies against six HLAs and TLRS/MD complex. So far, this protein and multiepitope have never been characterized as vaccine targets against Shigella dysenteriae. The current study proposed that V9 could be a significant vaccine candidate against shigellosis and to ascertain that further experiments may be applied by the scientific community focused on shigellosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.